Page 3 - புற்றுநோய் ஆராய்ச்சி ஆண்டு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from PR Newswire. The AP news staff was not involved in its creation. I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S. February 5, 2021 GMT I-MAB Logo (PRNewsfoto/I-Mab Biopharma) SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprietary and highly differentiated CD73 antibody, uliledlimab (also known as TJD5, or TJ004309) in advanced solid tumors. The Company plans to present detailed clinical results at select scientific conferences this year.

United statesHong kongSan diegoEmilie wuJoan shenGigi fengJielun zhuExchange commissionAmerican association of cancer research annual meetingPiacente group incAmerican associationCancer research annualPrivate securities litigation reform actChief financial officerChief communications officerPiacente group